Dicerna Pharmaceuticals Inc Revenue Growth Rates (DRNA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Dicerna Pharmaceuticals Inc   (NASDAQ: DRNA)
 

DRNA's Revenue Growth by Quarter and Year

Dicerna Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DRNA Revenue (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
4th Quarter December -
3rd Quarter September 62.95
2nd Quarter June 41.34
1st Quarter March 47.60
FY 151.89

DRNAs Annual Revenue
Dicerna Pharmaceuticals Inc 's Revenue in the fiscal year 2020 $ 164.31 millions
Dicerna Pharmaceuticals Inc 's Revenue in the fiscal year 2019 $ 23.90 millions
Dicerna Pharmaceuticals Inc 's Revenue in the fiscal year 2018 $ 6.18 millions
Dicerna Pharmaceuticals Inc 's Revenue in the fiscal year 2017 $ 2.28 millions
Dicerna Pharmaceuticals Inc 's Revenue in the fiscal year 2016 $ 0.30 millions




DRNA Revenue third quarter 2021 Y/Y Growth Comment
Dicerna Pharmaceuticals Inc reported Revenue improvement of 28.79% year on year in the third quarter 2021, to $ 62.95 millions, this is lower than Dicerna Pharmaceuticals Inc 's recent average Revenue surge of 329.54%.

Looking into third quarter 2021 results within Major Pharmaceutical Preparations industry 90 other companies have achieved higher Revenue growth. While Dicerna Pharmaceuticals Inc ' s Revenue rise of 28.79% ranks overall at the positon no. 1226 in the third quarter 2021.


DRNA Revenue ( Y/Y Growth %) 2021
 2020 2019 2018
4th Quarter December - 478.53 % 359.74 % 8.45 %
3rd Quarter September 28.79 % 507.96 % 418.71 % 229.79 %
2nd Quarter June 2.2 % 612.15 % 266.45 % 520 %
1st Quarter March 39.88 % 994.21 % 100.65 % 1092.31 %
FY   - 587.24 % 286.27 % -

Financial Statements
Dicerna Pharmaceuticals Inc 's third quarter 2021 Revenue $ 62.95 millions DRNA's Income Statement
Dicerna Pharmaceuticals Inc 's third quarter 2020 Revenue $ 48.88 millions Quarterly DRNA's Income Statement


DRNA Revenue (Quarter on Quarter Growth %)

 2021
 2020 2019 2018
4th Quarter December - -16.2 % -11.94 % -0.65 %
3rd Quarter September 52.28 % 20.84 % 41.55 % 0 %
2nd Quarter June -13.15 % 18.87 % 82.64 % 0 %
1st Quarter March 16.21 % 380.65 % 101.95 % 9.15 %
FY (Year on Year)   - 587.24 % 286.27 % -


Back to DRNA Growth rate Comparisons >> Back to DRNA Growth rate Comparisons >>


Revenue third quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #91
Healthcare Sector #198
Overall #1226

Revenue Y/Y Growth Statistics
High Average Low
1061.65 % 329.54 % -100 %
(Mar 31 2018)   (Jun 30 2016)
Revenue third quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #91
Healthcare Sector #198
Overall #1226
Revenue Y/Y Growth Statistics
High Average Low
1061.65 % 329.54 % -100 %
(Mar 31 2018)   (Jun 30 2016)

Revenue by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Dicerna Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
380.62 % 44.18 % -100 %
(Mar 31 2020)  


DRNA's III. Quarter Q/Q Revenue Comment
Dicerna Pharmaceuticals Inc achieved in the III. Quarter 2021 above company average sequential Revenue jump of 52.28%, to $ 62.95 millions, from $41.34 millions in the second quarter.
DRNA is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 54 other companies have achieved higher Revenue quarter on quarter growth. While Dicerna Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 340.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #55
Healthcare Sector #91
Overall #340
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #55
Healthcare Sector #91
Overall #340
Revenue Q/Q Growth Statistics
High Average Low
380.62 % 44.18 % -100 %
(Mar 31 2020)  


DRNA's III. Quarter Q/Q Revenue Comment
Dicerna Pharmaceuticals Inc achieved in the III. Quarter 2021 above company average sequential Revenue jump of 52.28%, to $ 62.95 millions, from $41.34 millions in the second quarter.
DRNA is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 54 other companies have achieved higher Revenue quarter on quarter growth. While Dicerna Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 340.


Dicerna Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2021)		 12 Months Ending
(Jun 30 2021)		 12 Months Ending
(Mar 31 2021)		 12 Months Ending
(Dec 31 2020)		 12 Months Ending
(Sep 30 2020)
Cumulative Revenue 12 Months Ending $ 192.85 $ 178.77 $ 177.88 $ 164.31 $ 130.43
Y / Y Revenue Growth (TTM) 47.86 % 99.54 % 224.45 % 587.36 % 610.22 %
Year on Year Revenue Growth Overall Ranking # 72 # 273 # 115 # 14 # 15
Seqeuential Revenue Change (TTM) 7.88 % 0.5 % 8.26 % 25.97 % 45.58 %
Seq. Revenue Growth (TTM) Overall Ranking # 644 # 2823 # 314 # 116 # 593


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2021 period, Dicerna Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 193 millions, company would post below average annual Revenue growth of 45.58% year on year, if the fiscal year would end at Sep 30 2021.
A slow-down in the Dicerna Pharmaceuticals Inc 's Revenue growth from the 41.34% growth in Jun 30 2021.

Within the Healthcare sector 24 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 72, from total ranking in previous quarter at 273.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 62
Healthcare Sector # 25
Overall # 72

Revenue TTM Y/Y Growth Statistics
High Average Low
904.44 %
 369.01 %
47.86 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 62
Sector # 153
S&P 500 # 644
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2021 period, Dicerna Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 193 millions, company would post below average annual Revenue growth of 47.86% year on year, if the fiscal year would end at Sep 30 2021.
A slow-down in the Dicerna Pharmaceuticals Inc 's Revenue growth from the 41.34% growth in Jun 30 2021.

Within the Healthcare sector 24 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 72, from total ranking in previous quarter at 273.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 62
Healthcare Sector # 25
Overall # 72

Revenue TTM Y/Y Growth Statistics
High Average Low
904.44 %
369.01 %
47.86 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 62
Sector # 153
S&P 500 # 644




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
DRNA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2021 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2021
Deciphera Pharmaceuticals Inc 50.30%$ 50.301 millions
Adaptive Biotechnologies Corporation50.07%$ 50.070 millions
Maxcyte inc 49.93%$ 49.929 millions
Alnylam Pharmaceuticals Inc 49.09%$ 49.089 millions
1life Healthcare Inc 48.85%$ 48.852 millions
Syros Pharmaceuticals Inc 48.82%$ 48.824 millions
La Jolla Pharmaceutical Company46.76%$ 46.759 millions
Agilon Health Inc 46.67%$ 46.670 millions
Cutera Inc 46.64%$ 46.642 millions
Electromedical Technologies Inc 46.28%$ 46.285 millions
Aerie Pharmaceuticals Inc 45.97%$ 45.974 millions
Epizyme Inc.45.85%$ 45.850 millions
Biolase Inc 45.76%$ 45.756 millions
Tandem Diabetes Care Inc 45.33%$ 45.326 millions
Acutus Medical Inc 45.00%$ 45.005 millions
Mannkind Corporation44.68%$ 44.678 millions
Butterfly Network Inc 44.26%$ 44.262 millions
Tela Bio Inc 44.06%$ 44.062 millions
American Shared Hospital Services43.77%$ 43.774 millions
Htg Molecular Diagnostics Inc41.83%$ 41.827 millions
Iradimed Corporation41.67%$ 41.670 millions
Caredx Inc 41.63%$ 41.635 millions
T2 Biosystems Inc 41.62%$ 41.621 millions
Optinose Inc 41.40%$ 41.397 millions
Global Blood Therapeutics Inc.41.10%$ 41.104 millions
Somalogic Inc 40.46%$ 40.462 millions
Kymera Therapeutics Inc 39.93%$ 39.930 millions
Jazz Pharmaceuticals Plc39.48%$ 39.479 millions
Rxsight Inc 38.75%$ 38.753 millions
Avita Medical Inc 38.74%$ 38.735 millions


About Dicerna Pharmaceuticals Inc Revenue Growth Rates (DRNA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.